Differential effects of MAPK pathway inhibitors on migration and invasiveness of BRAFV600E mutant thyroid cancer cells in 2D and 3D culture

被引:23
作者
Ingeson-Carlsson, Camilla [1 ]
Martinez-Monleon, Angela [1 ]
Nilsson, Mikael [1 ]
机构
[1] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Sahlgrenska Canc Ctr, SE-40530 Gothenburg, Sweden
基金
瑞典研究理事会;
关键词
Thyroid; Cancer; BRAF; MEK; U0126; PLX4720; Migration; 3D; KAPPA-B ACTIVATION; BRAF MUTATIONS; CONSTITUTIVE ACTIVATION; MESENCHYMAL TRANSITION; TUMOR MICROENVIRONMENT; PROMOTES INVASIVENESS; MEK INHIBITION; KINASE; RESISTANCE; CARCINOMA;
D O I
10.1016/j.yexcr.2015.08.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor microenvironment influences targeted drug therapy. In this study we compared drug responses to RAF and MEK inhibitors on tumor cell migration in 2D and 3D culture of BRAF(V600E) mutant cell lines derived from human papillary (BCPAP) and anaplastic (SW1736) thyroid carcinomas. Scratch wounding was compared to a double-layered collagen gel model developed for analysis of directed tumor cell invasion during prolonged culture. In BCPAP both PLX4720 and U0126 inhibited growth and migration in 2D and decreased tumor cell survival in 3D. In SW1736 drugs had no effect on migration in 2D but decreased invasion in 3D, however this related to reduced growth. Dual inhibition of BRAF(V600E) and mEK reduced but did not prevent SW1736 invasion although rebound phosphorylation of ERK in response to PLX4720 was blocked by U0126. These findings indicate that anti-tumor drug effects in vitro differ depending on culture conditions (2D vs. 3D) and that the invasive features of anaplastic thyroid cancer depend on non-MEK mechanism(s). (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:127 / 135
页数:9
相关论文
共 39 条
  • [1] V600EBRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression through a Snail-dependent mechanism
    Baquero, Pablo
    Sanchez-Hernandez, Irene
    Jimenez-Mora, Eva
    Orgaz, Jose L.
    Jimenez, Benilde
    Chiloeches, Antonio
    [J]. CANCER LETTERS, 2013, 335 (01) : 232 - 241
  • [2] BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment
    Begum, S
    Rosenbaum, E
    Henrique, R
    Cohen, Y
    Sidransky, D
    Westra, WH
    [J]. MODERN PATHOLOGY, 2004, 17 (11) : 1359 - 1363
  • [3] Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression
    Bissell, Mina J.
    Hines, William C.
    [J]. NATURE MEDICINE, 2011, 17 (03) : 320 - 329
  • [4] BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy
    Bommarito, Alessandra
    Richiusa, Pierina
    Carissimi, Elvira
    Pizzolanti, Giuseppe
    Rodolico, Vito
    Zito, Giovanni
    Criscimanna, Angela
    Di Blasi, Francesco
    Pitrone, Maria
    Zerilli, Monica
    Amato, Marco C.
    Spinelli, Gaetano
    Carina, Valeria
    Modica, Giuseppe
    Latteri, M. Adelfio
    Galluzzo, Aldo
    Giordano, Carla
    [J]. ENDOCRINE-RELATED CANCER, 2011, 18 (06) : 669 - 685
  • [5] CELL-MOVEMENT ELICITED BY EPIDERMAL GROWTH-FACTOR RECEPTOR REQUIRES KINASE AND AUTOPHOSPHORYLATION BUT IS SEPARABLE FROM MITOGENESIS
    CHEN, P
    GUPTA, K
    WELLS, A
    [J]. JOURNAL OF CELL BIOLOGY, 1994, 124 (04) : 547 - 555
  • [6] The tumor microenvironment is a dominant force in multidrug resistance
    Correia, Ana Luisa
    Bissell, Mina J.
    [J]. DRUG RESISTANCE UPDATES, 2012, 15 (1-2) : 39 - 49
  • [7] Estrogen Induces Metastatic Potential of Papillary Thyroid Cancer Cells through Estrogen Receptor α and β
    Dong, Wenwu
    Zhang, Hao
    Li, Jing
    Guan, Haixia
    He, Liang
    Wang, Zhihong
    Shan, Zhongyan
    Teng, Weiping
    [J]. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2013, 2013
  • [8] The Epithelial-Mesenchymal Transition (EMT) Regulatory Factor SLUG (SNAI2) Is a Downstream Target of SPARC and AKT in Promoting Melanoma Cell Invasion
    Fenouille, Nina
    Tichet, Melanie
    Dufies, Maeva
    Pottier, Anais
    Mogha, Ariane
    Soo, Julia K.
    Rocchi, Stephane
    Mallavialle, Aude
    Galibert, Marie-Dominique
    Khammari, Amir
    Lacour, Jean-Philippe
    Ballotti, Robert
    Deckert, Marcel
    Tartare-Deckert, Sophie
    [J]. PLOS ONE, 2012, 7 (07):
  • [9] Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
    Flaherty, Keith T.
    Robert, Caroline
    Hersey, Peter
    Nathan, Paul
    Garbe, Claus
    Milhem, Mohammed
    Demidov, Lev V.
    Hassel, Jessica C.
    Rutkowski, Piotr
    Mohr, Peter
    Dummer, Reinhard
    Trefzer, Uwe
    Larkin, James M. G.
    Utikal, Jochen
    Dreno, Brigitte
    Nyakas, Marta
    Middleton, Mark R.
    Becker, Juergen C.
    Casey, Michelle
    Sherman, Laurie J.
    Wu, Frank S.
    Ouellet, Daniele
    Martin, Anne-Marie
    Patel, Kiran
    Schadendorf, Dirk
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (02) : 107 - 114
  • [10] Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
    Flaherty, Keith T.
    Puzanov, Igor
    Kim, Kevin B.
    Ribas, Antoni
    McArthur, Grant A.
    Sosman, Jeffrey A.
    O'Dwyer, Peter J.
    Lee, Richard J.
    Grippo, Joseph F.
    Nolop, Keith
    Chapman, Paul B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (09) : 809 - 819